EchoSolv HF FDA application update

Key points

• Echo IQ is working to resolve FDA concerns on EchoSolv HF
• FDA's feedback pertains to statistical analysis for clinical validation
• Multiple pathways considered for FDA clearance

Full summary

Echo IQ Limited is working with regulatory consultants and legal counsel to address the FDA's Not Substantially Equivalent (NSE) determination for its EchoSolv HF 510(k) application. The company believes there is a clear path forward to obtaining FDA clearance, which could be achieved over the coming quarters. The FDA's feedback is limited to aspects of statistical analysis supporting clinical validation, with no concerns raised about the underlying technology or core functionality of EchoSolv HF. Echo IQ is assessing multiple pathways to achieve clearance, including an administrative appeal, FDA Ombudsman review, or a new 510(k) submission.

Outlook

Echo IQ remains confident that clearance for EchoSolv HF remains achievable under the 510(k) route.